News

Enter your email address to get Core One Labs News Alerts.

News

Enter your email address to get Core One Labs News Alerts.
Company News
March 19, 2022
Core One Labs to Investigate Soliciting Investment and Potential Takeover Opportunities
Vancouver, British Columbia, Canada – March 19, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
March 15, 2022
Core One’s Vocan Biotechnologies and Awakened Biosciences Collaborate to Advance Vocan’s Mass Production Capabilities
Vancouver, British Columbia, Canada – March 15, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6,...
Read more
Company News
March 12, 2022
Core One Labs Proceeds with Next Milestone Achievement: To Produce Psilocybin
Successful Breakthrough of Biosynthetic Psilocybin Production Method Progressing Quickly Vancouver, British Columbia, Canada – March 12, 2022 – Core One Labs...
Read more
Company News
March 04, 2022
Core One Labs’ Akome Biotech Initiates Neurogenesis Stimulation and Modeling Studies: Advancing its Proprietary Psychedelic-based Pharmaceutical Formulations
Vancouver, British Columbia, Canada – March 4, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (the...
Read more
Company News
March 03, 2022
Core One Labs Announces Successful Proof-of-Concept for Biosynthetic N-methyltryptamine (NMT)
VANCOUVER, British Columbia, March 3, 2022 - Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core...
Read more
Company News
February 21, 2022
Core One Labs’ Files Milestone Patent for Protection of its Recombinant Production System for Optimized Biosynthetic N-methyltryptamine (NMT)
Vancouver, British Columbia, Canada – February 21, 2022 – Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD6, WKN: A3CSSU) (“Core One”...
Read more